UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?

Miller, RE; Crusz, SM; Ledermann, JA; (2019) Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care? Future Oncology 10.2217/fon-2019-0057. (In press).

[img] Text
Ledermann_Olaparib maintenance for first-line treatment of ovarian cancer. Will SOLO1 reset the standard of care_AAM.pdf - Accepted version
Access restricted to UCL open access staff until 1 May 2020.

Download (401kB)

Abstract

Maintenance therapy with PARP inhibitors has heralded a new era in the management of recurrent epithelial ovarian cancer. The greatest effect is seen in women with BRCA1/2 tumors but those without this mutation also benefit. However, in most patients, the drugs eventually fail to prevent progression, so alternative strategies are needed. The SOLO1 trial randomized women with BRCA1/2-mutated advanced ovarian cancer to olaparib or placebo maintenance after first-line chemotherapy. Olaparib significantly improved progression-free survival to a degree that has not been seen in other first-line trials in ovarian cancer. This landmark trial is likely to change practice for this group of women. Here, we focus on the SOLO1 results in the context of the current management of advanced ovarian cancer.

Type: Article
Title: Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Location: England
DOI: 10.2217/fon-2019-0057
Publisher version: https://doi.org/10.2217/fon-2019-0057
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: mutation, PARP inhibitor, SOLO1, olaparib, ovarian cancer
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10074275
Downloads since deposit
2Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item